Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Immunoglobulin
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy, Safety and Pharmacokinetic of Virchow IVIG in PID Patients
Details : V-Immune (Immunoglobulin) is a Antibody drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Immunologic Deficiency Syndromes.
Product Name : V-Immune
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 12, 2025
Lead Product(s) : Immunoglobulin
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gam-COVID-Vac
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : The Russian Direct Investment Fund
Deal Size : Undisclosed
Deal Type : Partnership
RDIF Partners with Virchow Biotech for Production of Sputnik V Vaccine in India
Details : Agreement will facilitate the full-scale local production of the Sputnik V vaccine in India and to supply our international partners globally.
Product Name : Sputnik V
Product Type : Vaccine
Upfront Cash : Undisclosed
March 22, 2021
Lead Product(s) : Gam-COVID-Vac
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : The Russian Direct Investment Fund
Deal Size : Undisclosed
Deal Type : Partnership
Reset All
